Table 3 Relationship between L1CAM and p53 expression in high-risk endometrial cancer grouped by histology

From: Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer

 

L1CAM expression

 

0%

<10%

10–50%

>50%

Total (%)

Total ( P=0.001)

 p53-wild-type

23 (31.1)

27 (36.5)

15 (20.3)

9 (12.1)

74

 p53-mutant

8 (19.0)

7 (16.7)

8 (19.0)

19 (45.2)

42

 Total

31 (26.7)

34 (29.3)

23 (19.8)

28 (24.2)

116

Endometrioid ( P=0.471)

 p53-wild-type

20 (31.2)

25 (39.1)

13 (20.3)

6 (9.4)

64

 p53-mutant

8 (36.4)

5 (22.7)

5 (22.7)

4 (18.2)

22

 Total

28 (32.6)

30 (34.9)

18 (20.9)

10 (11.6)

86

Non-endometrioida (P=0.031)

 p53-wild-type

3 (30.0)

2 (20.0)

2 (20.0)

3 (30.0)

10

 p53-mutant

0 (0.0)

2 (10.0)

3 (15.0)

15 (75.0)

20

 Total

3 (10.0)

4 (13.3)

5 (16.7)

18 (60.0)

30

  1. Abbreviation: L1CAM, L1 cell adhesion molecule.
  2. aThe non-endometrioid endometrial carcinoma subgroup consists of clear-cell (N=18; eight p53-mutant tumors, of which six L1CAM >50%) and serous carcinomas (N=12; all p53-mutant, of which nine L1CAM >50%).
Back to article page